The core technology of Amberstone Biosciences Inc is a proprietary single cell platform designed by the firm's principals to enable deep survey of immune repertoire to identify rare antibodies. The platform also enables a new approach to being able to interrogate TCR and its interaction with cognate antigens. A biotherapeutics company developing a novel class of targeted and conditionally active immunotherapeutics to treat solid tumor cancers and other diseases, Amberstone Biosciencesâ pipeline is driven by an innovative high-throughput single-cell functional discovery platform and strong expertise in an interdisciplinary field of biology, engineering, and therapeutic developmen
